Background: Several studies have shown that pregnancy reduces multiple sclerosis (MS)
relapses, which increase in the early postpartum period. Postpartum relapse risk has been …

Objective To test the hypothesis that immunotherapy prevents long-term disability in
relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. …

Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment
of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT …

Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells,
reduces the frequency of relapses by 46% and disability worsening by 40% compared with …

Methods The COVID-19 study (clinicaltrials. gov: NCT04354519) is a prospective observational
cohort launched on 17 March 2020 as part of the UKMSR (Ethics: 16/SW/0194). PwMS …

Background: People with MS (pwMS) have had higher rates of anxiety and depression than
the general population before the COVID-19 pandemic, placing them at higher risk of …

Neurologists increasingly use anti-CD20 therapies, including for women of childbearing age,
despite these medications being unlicensed for use in pregnancy. Current evidence …

Objective: To evaluate the role of Mycoplasma hominis as a vaginal pathogen. Design:
Prospective study comprising detailed history, clinical examination, sexually transmitted infection (…

Background Infections can trigger exacerbations of multiple sclerosis (MS). The effects of the
coronavirus disease 2019 (COVID-19) on MS are not known. The aim of this study was to …

Background: Several natural history studies on primary progressive multiple sclerosis (PPMS)
patients detected a consistent heterogeneity in the rate of disability accumulation. …